D. Portman

发表

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.

D. Portman, M. Gass, 2014, Maturitas.

Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review

R. Kagan, D. Portman, S. Goldstein, 2019, Climacteric : the journal of the International Menopause Society.

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial

R. Rosen, G. Constantine, S. Kingsberg, 2014, Climacteric : the journal of the International Menopause Society.

Women's experience of vulvovaginal symptoms associated with menopause

R. Rosen, J. Simon, S. Kingsberg, 2019, Menopause.

Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause

I. Goldstein, J. Simon, D. Archer, 2019, Expert review of endocrinology & metabolism.

Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials

J. Simon, D. Portman, A. Kaunitz, 2013, Menopause.

A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice.

C. Pashos, Qin Wang, L. Shulman, 2008, Journal of women's health.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

F. Labrie, C. Martel, D. Archer, 2015, Menopause.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

F. Labrie, C. Martel, D. Archer, 2016, Menopause.

Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy

G. Bachmann, J. Simon, D. Portman, 2013, Menopause.

The creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?

J. Trussell, D. Portman, 2013, Contraception.

Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials

D. Portman, D. Eisenberg, Patty Cason, 2021, Advances in Therapy.

The emerging role of obesity in short-acting hormonal contraceptive effectiveness.

J. Trussell, D. Portman, A. Edelman, 2017, Contraception.

One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy

N. Iyer, L. Shulman, J. Yeaw, 2015, Menopause.

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study

L. Derogatis, F. Labrie, C. Martel, 2016, Hormone molecular biology and clinical investigation.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society

D. Portman, M. Gass, 2014, Menopause.

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

G. Bachmann, D. Portman, P. Koninckx, 2013, Climacteric : the journal of the International Menopause Society.

A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.

D. Portman, W. Wilborn, J. Symons, 2003, American journal of obstetrics and gynecology.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

D. Portman, M. Gass, 2014, Climacteric : the journal of the International Menopause Society.

Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause

D. Portman, A. Kaunitz, J. Lippman, 2014, Menopause.

Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.

R. Nappi, D. Portman, S. Palacios, 2014, Maturitas.

Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.

S. Kingsberg, D. Portman, R. Kissling, 2017, The journal of sexual medicine.

Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.

D. Portman, A. Kaunitz, B. Howard, 2014, Contraception.

Altering the Hormone-free Interval With Extended-cycle Contraception

D. Portman, 2006 .

Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.

D. Portman, W. Gibbons, F. Anderson, 2006, American journal of obstetrics and gynecology.

Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.

D. Portman, W. Gibbons, F. Anderson, 2006, Contraception.

New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.

D. Mishell, D. Archer, C. Westhoff, 2015, Contraception.

Original research article New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study

D. Mishell, D. Archer, C. Westhoff, 2015 .

P-1 . The Vulvovaginal Atrophy Questionnaire ( VVAQ ) : A Novel Patient-Reported Outcome ( PRO ) for Assessing Symptoms of Vulvovaginal Atrophy in Menopausal Women

R. Rosen, J. Simon, S. Kingsberg, 2017 .

Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.

D. Portman, K. Reape, A. Kaunitz, 2009, Contraception.

Failure of a Meta-analysis: A Commentary on Glen Spielmans’s “Re-Analyzing Phase III Bremelanotide Trials for ‘Hypoactive Sexual Desire Disorder in Women’”

J. Simon, A. Clayton, J. Lucas, 2021, Journal of sex research.

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

J. Simon, A. Clayton, J. Lucas, 2019, Obstetrics and gynecology.

Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial

L. Derogatis, I. Goldstein, C. Spana, 2016, Women's health.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

D. Portman, M. Gass, 2014, Climacteric : the journal of the International Menopause Society.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

L. Derogatis, F. Labrie, C. Martel, 2015, The journal of sexual medicine.

Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women

F. Labrie, C. Martel, D. Archer, 2015, Menopause.

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

C. Labrie, F. Labrie, C. Martel, 2015, Maturitas.

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.

J. Simon, D. Portman, R. Mabey, 2014, Maturitas.

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

J. Simon, A. Clayton, J. Lucas, 2019, Obstetrics and gynecology.

Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.

L. Derogatis, J. Simon, D. Portman, 2018, The journal of sexual medicine.

Bremelanotide for Female Sexual Dysfunctions: Responder Analyses From a Phase 2B Dose-Ranging Study

L. Derogatis, J. Edelson, R. Jordan, 2014 .

Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses From a Phase 2B Dose-Ranging Study

J. Edelson, A. Clayton, R. Jordan, 2014 .

Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

J. Simon, A. Clayton, J. Lucas, 2022, Journal of women's health.

Safety Profile of Bremelanotide Across the Clinical Development Program.

J. Simon, A. Clayton, J. Lucas, 2022, Journal of women's health.

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)

C. Labrie, F. Labrie, C. Martel, 2015, Menopause.

Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause

R. Kagan, D. Portman, M. Sweeney, 2014, Menopause.

Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy

C. Labrie, F. Labrie, C. Martel, 2015, Climacteric : the journal of the International Menopause Society.

017 Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD) in the RECONNECT Study: Efficacy Analyses in Study Completers and Responders

C. Spana, J. Simon, A. Clayton, 2017 .

Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.

D. Portman, S. Damodaran, H. Moore, 2022, Journal of Clinical Oncology.

Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill: A Randomized Controlled Trial

D. Mishell, D. Archer, C. Westhoff, 2014, Obstetrics and gynecology.

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

D. Apter, P. Darney, D. Archer, 2019, The Lancet. Global health.

Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.

D. Mishell, D. Archer, C. Westhoff, 2015, Contraception.

Incremental direct and indirect costs of untreated vasomotor symptoms

P. Sarrel, M. Duh, D. Portman, 2015, Menopause.

To the Editor.

F. Labrie, C. Martel, D. Archer, 2016, Menopause.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society

D. Portman, M. Gass, 2014, The journal of sexual medicine.

021 Correlation of Physiologic Markers of Vulvovaginal Atrophy and Symptom Severity in Postmenopausal Women with Genitourinary Syndrome of Menopause

M. Krychman, D. Portman, J. Symons, 2016 .

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

L. Derogatis, F. Labrie, C. Martel, 2015, The journal of sexual medicine.

In Reply.

F. Labrie, C. Martel, Yuyong Ke, 2018, Menopause.